PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

New NHS DNA test could ‘rapidly diagnose’ rare illnesses in babies

A new form of DNA testing could rapidly diagnose rare diseases in critically ill babies and children, potentially benefitting up to 700 patients each year.

The new technique being dubbed “whole exome sequencing” has been tested on 80 babies and children, with almost half being given a diagnosis for their rare disease as a result.

The test “doubles” the chance of a diagnosis and can reveal what is wrong with patients in days rather than weeks, “reducing waits for worried families” claims NHS England.

The sequencing technique can identify a range of potentially life-threatening conditions all in one go, rather than standard tests which usually are limited to looking for specific conditions. It can also detect rare neurological, metabolic or other conditions by identifying genetic mutations and helps to show which patients are unlikely to respond to particular treatments – saving unnecessary medication and potential side effects.

The “quick and accurate” test means “rapid diagnosis and reassurance for families when they need it most” and can “give babies and children the best chance of a healthy and happy life” commented Simon Stevens, chief executive of NHS England.

He continued to say “In the last year alone, scores of patients have received game-changing new treatments such as CAR-T therapy and targeted radiotherapy at the NHS’s new £125 million Proton Beam centre.

“Over the next decade the NHS will continue to expand the range of personalised, precision medicines, including rolling out genomic testing to all people with rare diseases and patients with cancer.”

The technology has also been hailed as “game changing” by health and social care secretary Matt Hancock, who called it “one step forward.”

He continued to say that “over the coming years we will expand the use of genomic testing right across the NHS. It’s all part of our NHS Long Term Plan, backed by our record financial commitment for the NHS of £33.9 billion extra a year within the next five years.”

The routine is part of the NHS’ Long Term Plan, which intends to use world leading technologies to improve care for the sickest infants.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026